Biovie Inc (BIVI) Stock Price, Quote & News

Company Profile

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was...

Industry: Biotechnology

Sector: Healthcare

Phone: 775 888 3162

Website: bioviepharma.com

Address:

680 West Nye Lane, Suite 204, Carson City, United States

Thestocktraderhubzee Jun. 25 at 10:04 AM

WATCHLIST JUN 25 2025 $SNDX Syndax Pharmaceuticals Announces That The FDA Has Granted Priority Review For Its Supplemental New Drug Application For Revuforj In Relapsed or Refractory mNPM1 Acute Myeloid Leukemia $BIVI BioVie To Present Decentralized Design And Patient Experience Of Phase 2 SUNRISE-PD Clinical Trial Evaluating Bezisterim In Early Parkinson's Disease At Advanced Therapeutics In Movement & Related Disorders Congress $EYEN Reported June 23, 2025, Eyenovia PIPE Financing Enabled The Co To Acquire 1,040,584.5 HYPE At An Average Price Of ~$34 Per Token; Co Intends To Initiate Its Own Network Validator Alongside An Ecosystem Partner; Eyenovia Is Expected To Change Its Name And Ticker To "Hyperion DeFi" And "HYPD" $RKLB Rocket Lab Announces 'Get The Hawk Outta Here' Mission Launch Window Opens Jun. 26 At 17:00 UTC $JYD Jayud Global Logistics Secures $4.2M Government Subsidy From The Shenzhen Transportation Bureau For Charter Flight Operations

0 · Reply

Tradebait88 Jun. 25 at 1:20 AM

$BIVI p2 poster being presented friday

0 · Reply

BullSignalPro Jun. 24 at 8:09 PM

$BIVI BioVie Showcases At-Home Parkinson’s Trial Design at Movement Disorders Congress BioVie (NASDAQ: BIVI) will present a poster on its innovative hybrid Phase 2 SUNRISE-PD trial for NE3107 in early Parkinson’s disease, highlighting its decentralized, patient-friendly design allowing participation from home with remote neurologist oversight.

0 · Reply

Tradebait88 Jun. 24 at 4:26 PM

$BIVI 👀👀👀

0 · Reply

KatAtron Jun. 23 at 9:10 PM

$BIVI stock split approved.

1 · Reply

YasirTrades Jun. 18 at 6:58 PM

GLMD is a ticking time bomb 💣 Trading under cash. $20+ book. No debt. Tiny float. GLP-1 catalyst loading. Chart is coiled tight. When volume hits… boom 💥 100%+ upside? That might be conservative. $IMMX $VIRI $SERA $BIVI

0 · Reply

TJ12000 Jun. 16 at 6:36 AM

$BIVI what 💩 shit Kong … pay the class action u scamming mofo #cures baldness

0 · Reply

Christinapookie Jun. 12 at 2:27 PM

$BIVI give me a nice 3$ run

0 · Reply

RollingDollars Jun. 12 at 2:23 PM

$BIVI .

0 · Reply

Timtheshark Jun. 12 at 6:34 AM

$BIVI The split is just to stay listed. What matters is setup: SPA filing for ADDRESS-LC Phase 3 (liver) any day now, Phase 3 design ready, and ultra-low MC. LOI or partner usually announced before vote

0 · Reply

BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

May 14, 2025, 7:30 AM EDT - 6 weeks ago

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

Mar 27, 2025, 8:00 AM EDT - 3 months ago

BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025

Jan 26, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages BioVie Inc. (BIVI) Shareholders to Inquire about Securities Investigation

Jan 22, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Shareholders to Connect

Jan 19, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Shareholders to Reach Out

Jan 15, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Shareholders to Learn More About the Investigation

Jan 12, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Investors to Learn More About the Investigation

Jan 8, 2025, 10:00 AM EST - 6 months ago

BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 5, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Investors to Connect

Jan 2, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages BioVie Inc. (BIVI) Stockholders to Inquire about Securities Investigation

Dec 24, 2024, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Investors to Reach Out

Dec 22, 2024, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Stockholders to Reach Out

Dec 18, 2024, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Stockholders to Connect

Dec 15, 2024, 10:00 AM EST - 6 months ago

BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Dec 11, 2024, 2:00 PM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Stockholders to Learn More About the Investigation

Oct 28, 2024, 4:10 PM EDT - 8 months ago

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 28, 2024, 3:13 PM EDT - 8 months ago

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 24, 2024, 4:10 PM EDT - 8 months ago

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

Oct 23, 2024, 3:24 PM EDT - 8 months ago

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Oct 15, 2024, 8:00 AM EDT - 9 months ago

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

Oct 11, 2024, 9:00 AM EDT - 9 months ago

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GENE

Sep 25, 2024, 4:05 PM EDT - 9 months ago

BioVie Inc. Announces Closing of Public Offering

Sep 24, 2024, 2:08 PM EDT - 9 months ago

Crude Oil Gains Over 1%; BioVie Shares Plunge

Sep 23, 2024, 10:26 PM EDT - 9 months ago

BioVie Inc. Announces Pricing of Public Offering

Sep 23, 2024, 4:05 PM EDT - 9 months ago

BioVie Inc. Announces Proposed Public Offering

Sep 16, 2024, 8:00 AM EDT - 10 months ago

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

Sep 3, 2024, 8:00 AM EDT - 10 months ago

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

Aug 27, 2024, 8:45 AM EDT - 10 months ago

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

Aug 8, 2024, 6:00 AM EDT - 11 months ago

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease

Aug 6, 2024, 4:40 PM EDT - 11 months ago

BioVie Inc. Announces Reverse Stock Split

Jul 5, 2024, 9:00 AM EDT - 1 year ago

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

Jun 21, 2024, 9:00 AM EDT - 1 year ago

BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MOB

Jun 20, 2024, 8:00 AM EDT - 1 year ago

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress

Jun 12, 2024, 8:24 AM EDT - 1 year ago

Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26

May 22, 2024, 8:00 AM EDT - 1 year ago

BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients

Apr 29, 2024, 8:00 AM EDT - 1 year ago

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

Apr 25, 2024, 8:00 AM EDT - 1 year ago

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker Endpoints

Apr 18, 2024, 8:00 AM EDT - 1 year ago

BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation

Apr 12, 2024, 9:00 AM EDT - 1 year ago

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GENE

Mar 26, 2024, 10:30 AM EDT - 1 year ago

Lawsuit Notice: Investors who lost money with BioVie Inc. (NASDAQ: BIVI) shares should contact the Shareholders Foundation

Mar 19, 2024, 7:00 AM EDT - 1 year ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the Firm

Mar 17, 2024, 11:00 PM EDT - 1 year ago

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the Firm

Thestocktraderhubzee Jun. 25 at 10:04 AM

0 · Reply

Tradebait88 Jun. 25 at 1:20 AM

$BIVI p2 poster being presented friday

0 · Reply

BullSignalPro Jun. 24 at 8:09 PM

0 · Reply

Tradebait88 Jun. 24 at 4:26 PM

$BIVI 👀👀👀

0 · Reply

KatAtron Jun. 23 at 9:10 PM

$BIVI stock split approved.

1 · Reply

YasirTrades Jun. 18 at 6:58 PM

0 · Reply

TJ12000 Jun. 16 at 6:36 AM

$BIVI what 💩 shit Kong … pay the class action u scamming mofo #cures baldness

0 · Reply

Christinapookie Jun. 12 at 2:27 PM

$BIVI give me a nice 3$ run

0 · Reply

RollingDollars Jun. 12 at 2:23 PM

$BIVI .

0 · Reply

Timtheshark Jun. 12 at 6:34 AM

0 · Reply

retireonAsmlNvoCavaSn Jun. 11 at 2:04 AM

$BIVI split, raise, back to $1 level.. then I may invest some, which I believe will again be a split, then raise, then drop then possibly year end data for long COVID trial

1 · Reply

TraderMaker82 Jun. 10 at 8:44 PM

$BIVI Yup, They’re gonna split it again. 🤬🤬🤬 1-5 or 1-10…

0 · Reply

TraderMaker82 Jun. 10 at 6:42 PM

$BIVI If anyone hears news of a pending stock split let us know. I see nothing. I have someone of good standing telling me otherwise saying news came out June 8th. Please forgive me if I was wrong in my previous post. Peace and G/L 🍀

1 · Reply

TraderMaker82 Jun. 9 at 5:02 PM

$BIVI How is this bullish if they’re looking to take your shares?! Can someone tell me? Taking 5 or 10 and giving you 1 back is NOT A GOOD DEAL!

0 · Reply

Rod75b15 Jun. 9 at 3:20 PM

$BIVI

1 · Reply

Stmkr Jun. 9 at 11:28 AM

$BIVI Good recent summary PD readout late 2025/early 2026 Long COVID readout Q1-Q2 2026 https://youtu.be/whMokGdNyQQ?si=8CF0ZaeTDT4fJ9eK

0 · Reply

Stmkr Jun. 9 at 4:44 AM

$BIVI I dont see anything about plans for AD indication in the latesr 10Q. Has the company said anything? Have they completelt paused this program?

0 · Reply

Stmkr Jun. 9 at 4:35 AM

$BIVI This is getting interesting again with the funded long-COVID readout expectes 1H 2025. I dont like though the upcoming RS vote. Also what is happening with the AD indication? Nth about further plans for AD in the latest 10Q

0 · Reply

Punchedorphan Jun. 7 at 3:53 PM

$BIVI

0 · Reply

BrassTax Jun. 7 at 12:31 AM

$BIVI scam

0 · Reply

woolpourpis69 Jun. 3 at 2:57 PM

$BIVI

0 · Reply

tomweible May. 28 at 2:01 PM

$BIVI is hosting a virtual KOL investor event today at 12pm EDT on the urgent unmet needs and treatment landscape in #ParkinsonsDisease and the Company's ongoing SUNRISE-PD clinical trial in newly diagnosed patients. Register here: https://lifescievents.com/event/biovie-4/

0 · Reply

Market Cap	18.76M
Revenue (ttm)	0.00
Net Income (ttm)	-32.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	154,443
Avg Vol	458,666
Day's Range	N/A - N/A
Shares Out	18.57M
Stochastic %K	33%
Beta	0.76
Analysts	Strong Sell
Price Target	$5.50